BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-714@pharmaconomics
DTSTAMP:20260707T022134Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:QNRX Phase 3 — QRX003 (estimated date)
DESCRIPTION:Phase 3 trial results for QRX003 in Netherton Syndrome are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1671502/000110465926076822/tm2618505d1_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/714
URL:https://www.pharmaconomics.com/e/714
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:QNRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR